Mounjaro® (Tirzepatide)

KwikPens & Injectable Presentations for Global Pharmaceutical Supply

Reliable sourcing, pharmaceutical expertise and international supply support for qualified healthcare buyers, distributors, hospitals, and licensed medical importers.

Pen & Injectable Presentations

Multi-strength · Cold-chain packaged · Batch-documented for export

Export Compliance

GDP & Cold Chain

Documentation

COA & Certificate of Origin

Buyer Eligibility

Licensed B2B Entities Only

Mounjaro® at a Glance

Core pharmacological specifications for authorized medical importers and procurement officers.

Active Ingredient
Tirzepatide

First-in-class dual GIP/GLP-1 receptor agonist

Frequency
Once Weekly

Fixed day dosing schedule, independent of meals

Brand Name
Mounjaro®

Manufactured by Eli Lilly and Company

Prescription Status
Prescription Medicine (POM)

Restricted to licensed healthcare channels

Administration
Subcutaneous Injection

Administered into abdomen, thigh, or upper arm

Therapeutic Area
Type 2 Diabetes & Weight Management*

Indications vary by regional health authority

Two Pathways. One Active Ingredient.

Tirzepatide is a single molecule engineered to activate both GIP and GLP-1 hormone receptors.

Synergistic GIP & GLP-1 Receptor Activation

By mimicking both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), tirzepatide enhances first- and second-phase insulin secretion, decreases glucagon concentrations, and slows gastric emptying.

GIP

Incretin hormone pathway

+

GLP-1

Incretin hormone pathway

1. Blood Glucose Management

Improves glycemic control through glucose-dependent insulin secretion and suppression of inappropriately elevated glucagon.

2. Weight Management

Supports significant reductions in body weight through appetite regulation and reduced caloric intake.

3. Once-Weekly Administration

Optimized pharmacokinetic profile allowing stable once-weekly subcutaneous dosing for improved compliance.

All Mounjaro Strengths, In Stock for Export

Presentation availability is subject to current stock and manufacturer allocation. Submit a requirement to receive confirmed availability for your market.

*Indications and availability vary by country. Always verify local regulatory requirements before marketing or importing.

Clinical safety overview

Mounjaro® (Tirzepatide) is a prescription medicine that must be handled and dispensed in accordance with local regulatory guidelines.

Official Disclaimer: “Always refer to the locally approved product information and consult a qualified healthcare professional prior to administration or clinical procurement.”

Brand:

Mounjaro®

Active Molecule:

Tirzepatide

Manufacturer:

Eli Lilly & Company

Role of Divy Tradelink:

Sourcing & export partner

Mounjaro® by Eli Lilly

Mounjaro® is developed and manufactured by Eli Lilly and Company. Divy Tradelink operates independently as a specialized international pharmaceutical sourcing, export, and B2B supply partner.

How to Use Mounjaro®

Standard 5-step subcutaneous KwikPen administration workflow.

01

Choose Your Weekly Day

Take Mounjaro® once a week, preferably on the same day each week. Your healthcare professional will advise you on the appropriate dose and schedule.

02

Prepare Your Pen

Before use, check the pen and medication according to the instructions provided with the product. Follow the preparation steps specific to your Mounjaro® pen presentation.

03

Select Your Injection Site

Mounjaro® is injected under the skin of the abdomen, thigh, or upper arm. Follow your healthcare professional’s guidance on injection sites and technique.

04

Administer & Dispose Safely

Administer the injection according to the official pen instructions. After use, dispose of the pen or injection device appropriately according to local medical waste requirements.

Frequently Asked Questions

From sourcing to delivery, we ensure reliability at every step. Our operations follow strict quality and regulatory standards.

What is Mounjaro®?

Mounjaro® is a prescription injectable medicine containing Tirzepatide, indicated for the treatment of type 2 diabetes mellitus and adult weight management under qualified medical supervision.

Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, designed to augment insulin secretion and regulate glucose metabolism.
Yes. Mounjaro® is strictly a prescription-only medicine (POM) and must be prescribed by a licensed healthcare professional following clinical evaluation.
Mounjaro® is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day, with or without food.

Mounjaro® presentations, strengths and pack formats vary by market and current supply position. Share your destination and requirement so the export desk can confirm applicable options.

Yes. Divy Tradelink specializes in international pharmaceutical export, regulatory document support, and temperature-controlled cold-chain logistics to licensed distributors, hospitals, and clinics worldwide.

Depending on the destination and confirmed presentation, documentation support can include a Certificate of Analysis (COA), Certificate of Origin, Free Sale Certificate, product documentation, and export paperwork.
MOQs are tailored to B2B institutional buyers, wholesale distributors, and hospital procurement requirements. Please submit an availability enquiry for batch-specific MOQ details.